Skip to main content
Premium Trial:

Request an Annual Quote

Waters Sales and Earnings Rise, Despite Downturn in Mass Spec Sales for Proteomics

NEW YORK, Jan. 29 (GenomeWeb News) - Waters reported increased revenues and earnings for the fourth quarter of 2003 today, despite slow mass spec sales for proteomics.


The company's fourth quarter revenues increased to $275.1 million, from $256.4 million a year ago.


R&D expenses for the quarter climbed to $16.8 million, from $13.4 million during the same period last year.


Waters' net income surged to $58.4 million, or $.48 per share, for the quarter, compared with $40.3 million, or $.31 per share, the year before. This was despite a sharp 30 percent downturn in mass spec sales for the quarter, year over year, especially regarding proteomics-focused Q-TOF instruments.


As of Dec. 31, 2003, Waters had cash and cash equivalents of $356.8 million.


The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.